.Pharmacolibrary.Drugs.ATC.N.N03AX22 .Pharmacolibrary.Drugs.ATC.N.N03AX22| name: | Perampanel |
| ATC code: | N03AX22 | route: | oral |
| n-compartments | 1 |
Perampanel is a selective, non-competitive antagonist of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor, used as an antiepileptic drug for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy. It is approved for use in many countries as an adjunctive therapy.
Pharmacokinetic parameters reported for healthy adults after a single oral dose.
Li, S, et al., & Liu, Z (2024). Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real-world study. Epilepsia 65(6) 1687–1697. DOI:10.1111/epi.17954 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38572689
Hanaya, R, et al., & Inoue, Y (2023). Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy. Epilepsia open 8(4) 1369–1382. DOI:10.1002/epi4.12804 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37547978
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590